Institutional net value change of -$20.2B (1910 net sellers vs 1860 buyers) and 5 insider sales totaling $10.7M with zero purchases confirm convergence.

Confirmation

Further institutional liquidation or additional insider sales would confirm bearish momentum.

Invalidation Risk

A shift to insider buying or a reversal in institutional accumulation invalidates the bearish view.

AI-generated from public SEC disclosures and limited to historical data. Should not be relied upon as the sole basis for any investment decision.

Insider Trading (Form 4)

90d confidence

unique buyers

—

buy value

data as of 2026-07-17

12-Month Buy/Sell Activity

Feb 25

Feb 26

BuySell

Action	Insider	Title	Date	Value
Sell	Purdue David Ryan	SVP, Controller	2026-03-04	$1.22M
Sell	Siatis Perry C	EVP, GC AND SECRETARY	2026-03-02	$2.41M
Sell	Siatis Perry C	EVP, GC AND SECRETARY	2026-03-02	$612K
Sell	Siatis Perry C	EVP, GC AND SECRETARY	2026-03-02	$1.35M
Sell	Siatis Perry C	EVP, GC AND SECRETARY	2026-02-25	$5.15M
Sell	SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	2025-08-12	$8.41M
Sell	Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	2025-08-05	$2.00M
Sell	Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	2025-08-05	$641K

View all insider trades →

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-06

2026-07-06

AbbVie announced that its second-quarter 2026 earnings will include a $291 million pre-tax expense for acquired in-process research and development (IPR&D) and milestones, reducing both GAAP and adjusted earnings per share by $0.17. The company updated its adjusted earnings guidance for the quarter and the full year to reflect this charge. Its adjusted EPS is now expected to be between $3.57 and $3.61 for Q2, and between $13.91 and $14.11 for the full year.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ABBVIE INC (ABBV)?

Major stakeholders currently include BlackRock, Inc. ($32.8B), Vanguard Capital Management LLC ($25.0B), State Street CORP ($17.7B). Based on the latest 13F filings, there are a total of 4086 tracked investment funds and institutions maintaining positions in ABBV.

What is the overall institutional sentiment toward ABBV recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $20.3B, driven by 1860 managers accumulating shares while 1910 reduced their exposure.

Which institutions have been selling or reducing their ABBV positions?

In the latest period, 1713 funds trimmed their holdings, and 197 managers completely exited their positions. The aggregate reported sell value was $145.3B.

Are there any notable investors adding ABBV to their portfolios?

Yes, buying activity remains notable. 148 institutions opened new positions in {ticker}, and 1712 existing holders added to their shares. The total reported buy value for the quarter amounted to $127.1B.